Theratechnologies Announces Completion of Acquisition by Future Pak. Click here to learn more.

Theratechnologies Announces Completion of Acquisition by Future Pak. Click here to learn more.

Theratechnologies Announces Completion of Acquisition by Future Pak.
Click here
to learn more.

Health
innovation that
matters

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies.

We currently market prescription products for people with HIV in the United States.

Pipeline & Medicines

Product Pipeline & Portfolio

Theratechnologies develops and commercializes innovative therapies. The company currently commercializes three products in the field of HIV. EGRIFTA WR™, Trogarzo®, and Mytesi® are approved in the United States.

Company Announcements

Recent News

HIV
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Marketed
TROGARZO® / TROGARZO™ IV PUSH
EGRIFTA SV® / EGRIFTA WR®

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Marketed

Responsive Drug Pipeline Chart
HIV
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Marketed
Preclinical
Phase I
Phase II
Phase III
Approved
Marketed

Search

Theratechnologies